Slide 1: Investor Presentation May 2021
Working to improve your health INVESTOR PRESENTATION MAY 2021
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT for the financial year ended 31 March 2021. It is not prepared for any other purpose and must not be provided to any person other than the intended rec
Slide 3: AFT financials at a glance
AFT financials at a glance 120 113 100 106 Operating Revenue ( NZ$M) 10 year operating CAGR of 13% 80 85 80 69 60 64 56 49 40 40 33 34 28 20 23 26 17 12 8 - '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 Financial year ended 31 March Operating profit¹ Profit after tax¹ 15 10 Inv
Slide 4: FY2021 financial highlights
FY2021 financial highlights 54% Increase in number of countries Maxigesic sold in to 43 9% Increase in operating revenue from product sales to $111.0m 6% Decline in normalised operating profit1 to (+9% growth if adjusted for one off $1.7 million R&D credit in PY) $10.7m 164% Increase in normalised p
Slide 5: Revenue Growth
Revenue Growth FY2020 FY2021 60.0 60.0 68.3 • Continued growth in 61.4 established Australian 40.0 40.0 and New Zealand $m $m 30.1 markets 30.5 20.0 20.0 9.1 4.9 9.9 4.4 • Significant growth in - - product sales to Rest of the World 11% 1% 8% (10)% 47% product • sales growth Significant margin 4.7%
Slide 6: AFT Australasian product portfolio
AFT Australasian product portfolio AFT’s portfolio includes a broad range of 125+ proprietary, branded and generic products built on seven therapeutic pillars: Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Pain Combolieve Day/Night Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, Eyecare VitAPOS M
Slide 7: AFT Asia product portfolio
AFT Asia product portfolio AFT’s Asia portfolio includes a range of proprietary, branded and generic products which address the following therapeutic areas: Pain Maxigesic Medicated Ferro-sachets, Lipo VitC, Lipo VitD and expanding pipeline Vitamins – T Mall Dermatology Crystawash Extend Hand Saniti
Slide 8: AFT Global product portfolio
AFT Global product portfolio AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. It continues the development of its portfolio of repurposed medicines: Maxigesic, Pascomer, NasoSURF, Crystawash Extend and Crystaderm Maxigesi
Slide 9: Abbreviated Consolidated Income Statement
Abbreviated Consolidated Income Statement NZ#039;000's year ended 31 March 2021 % of 2020 % of revenue revenue Revenue 113,105 105,597 Gross Profit 48,741 43.1% 48,265 45.7% Underlying Operating Expenses and Other Income (38,033) 33.6% (36,843) 34.9% Underlying Operating Profit ¹ 10,708 9.5% 11,422 10.
Slide 10: Abbreviated Balance Sheet
Abbreviated Balance Sheet NZ#039;000's year ended 31 March 2021 2020 Current assets 64,693 49,217 Cash 3,209 6,119 Non-current assets 37,237 31,716 Total assets 105,139 87,052 Current liabilities 26,941 23,102 Current interest bearing liabilities 5,161 2,000 Non-current liabilities 3,242 3,495 Non-curr
Slide 11: Abbreviated Cashflow
Abbreviated Cashflow NZ#039;000's year ended 31 March 2021 2020 Net cash from operating activities 757 14,878 Net cash used in investing activities (6,231) (6,562) Net cash (used) / generated from financing activities 2,515 (9,118) Net increase / (decrease) in cash (2,959) (802) Impact of foreign excha
Slide 12: Normalised Operating profit progress
Normalised Operating profit progress NZ$ million Investor presentation May 2021 12
Slide 13: New Products build Revenue pipeline
New Products build Revenue pipeline Maxigesic o FDA CRL received for tablets indicating approvability after manufacturing site GMP audit o Maxigesic IV registrations successfully completed in now 21 countries o Maxigesic Oral Liquid awaiting first registrations in Europe and ANZ Maxigesic Hot Drink
Slide 14: Maxigesic Global Update
MAXIGESIC GLOBAL UPDATE Ire la n d – Tablets launched IV licensed [Oral Dose Forms & IV] U n ite d K in g d o m – Tablets la u n c h e d IV licensed Russia – Orals licensed Netherlands – IV licensed S in g a p o re & B ru n e i – Tablets la u n c h e d Austria – IV licensed China - licensing negotia
Slide 15: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered 90 80 70 60 50 40 30 85 20 54 Investor presentation May 2021 10 43 2 28 0 3 20 4 7 FY14 9 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 15
Slide 16: Outlook
Outlook Further Drive International Sales Keep accelerating number of new countries launched in such as Russia Growing sales in newly launched markets such as Canada, Germany, Switzerland Launching new line extensions – Maxigesic IV Extend International Licensing Finalise licensing agreement
Slide 17: Working to improve your health
Working to improve your health